Both Trastuzumab and Lapatinib have received approval by the FDA for the treatment of HER-2 positive breast cancer and are associated with improved clinical outcome in metastatic (Slamon et al. [2001]; Geyer et al. [2006]) and, for Trastuzumab, early stage HER-2 positive breast cancer (Romond et al. [2005]; Piccart-Gebhart et al. [2005]). The gene discussed is ERBB2; the disease is breast cancer.